Gapping up
In reaction to earnings/guidance:
- DNMR +11.8%, TLS +5.9%, HIPO +5.6%, SE +4.4%, FN +2.9%, PINC +2.5%, POWW +2.1%, AIT +1.9%, GOEV +1.2%, AG +1%
Other news:
- FBRX +15% (to announce top-line data from Phase 2 trial of FB-401 on Sept 7)
- HSDT +11.4% (announces FDA breakthrough device designation for the treatment of dynamic gait and balance deficits following a stroke)
- TLSA +4.2% (announces publication of a peer reviewed article on data from the clinical trial with intranasally administered Foralumab)
- ANDE +3.5% (sells railcar leasing business for $550 mln)
- GPK +2.2% (UK CMA is investigating the anticipated acquisition by Graphic Packaging Holding Company of AR Packaging Group AB)
- GMED +1.8% (receives FDA 510(k) clearance for Excelsius 3D)
- USDP +1.6% (expands downstream connectivity at Stroud terminal)
Analyst comments:
- APP +2.2% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
- BKR +0.6% (upgraded to Conviction Buy from Buy at Goldman)